Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Urologix

This article was originally published in The Gray Sheet

Executive Summary

Urologix: Files with SEC for a proposed secondary offering of 1.5 mil. shares of common stock. The Minneapolis maker of minimally invasive devices for treatment of urological diseases received FDA approval Aug. 22 for its Targis microwave therapy device for treating benign prostatic hyperplasia ("The Gray Sheet" Sept. 1, p. 4), and plans to use proceeds from the offering to fund sales and marketing efforts, "to expand manufacturing capacity, and for working capital and other general corporate purposes," the firm says. Underwriters BT Alex. Brown, Dain Bosworth and PaineWebber hold an over-allotment option for 225,000 additional shares...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT008969

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel